TUCSON, Arizona, USA, June 11, 2026
Roche Diagnostics has announced a significant expansion of its precision oncology diagnostics portfolio following European Union In Vitro Diagnostic Regulation (IVDR) approval for multiple label expansions of the VENTANA® MMR RxDx Panel. The approval broadens the companion diagnostic’s use across five cancer types and six therapeutic indications, enabling clinicians to identify eligible patients for several leading immunotherapy and targeted treatment regimens. The milestone reinforces Roche’s leadership in personalized healthcare and companion diagnostics, providing oncologists with a standardized method for determining mismatch repair (MMR) status, a critical biomarker that helps guide treatment decisions in multiple solid tumors. As precision medicine continues to transform cancer care, the expanded approval is expected to improve patient access to biomarker-driven therapies across Europe and other IVDR-regulated markets.
IVDR Approval Broadens Access to Precision Oncology Therapies
The expanded IVDR approval positions the VENTANA MMR RxDx Panel as one of the most comprehensive companion diagnostic tools available for evaluating mismatch repair status in cancer patients. The assay is now approved to support treatment decisions involving several major oncology therapies, including KEYTRUDA® (pembrolizumab), IMFINZI® (durvalumab), IMFINZI® plus LYNPARZA® (olaparib), and JEMPERLI® (dostarlimab). The expanded indications span multiple tumor types, including metastatic colorectal cancer, advanced or recurrent endometrial cancer, gastric cancer, small intestine cancer, and biliary tract cancer.
By identifying patients with either deficient mismatch repair (dMMR) or proficient mismatch repair (pMMR) tumors, the test enables clinicians to select therapies more likely to deliver meaningful clinical benefit. The approval reflects the increasing importance of biomarker-driven treatment strategies, where diagnostic testing plays a central role in matching patients with the most appropriate therapies based on the biological characteristics of their disease.
MMR Testing Supports Personalized Treatment Decisions
Advertisement
Mismatch repair deficiency has emerged as one of the most important predictive biomarkers in modern oncology. The body’s natural mismatch repair system continuously scans DNA for replication errors and corrects them before mutations accumulate. When this repair mechanism becomes deficient, cancer cells develop higher mutation rates, often making them more susceptible to immune checkpoint inhibitors such as PD-1 and PD-L1-targeted therapies. The VENTANA MMR RxDx Panel evaluates the expression of four key mismatch repair proteins—MLH1, MSH2, MSH6, and PMS2—using immunohistochemistry technology performed on Roche’s BenchMark ULTRA platform.
By providing standardized and reproducible assessment of MMR status, the test helps reduce variability in diagnostic interpretation and supports more confident clinical decision-making. The ability to accurately identify patients who may respond to immunotherapy is particularly important as oncology increasingly moves toward individualized treatment approaches designed to maximize efficacy while minimizing unnecessary exposure to therapies unlikely to provide benefit.
Companion Diagnostics Drive the Future of Precision Medicine
The latest approval further strengthens Roche’s position as a global leader in companion diagnostics and precision oncology solutions. Cancer remains one of the leading causes of death worldwide, responsible for nearly 10 million deaths annually, underscoring the urgent need for advanced diagnostic tools that can help optimize treatment selection. The expanded use of the VENTANA MMR RxDx Panel highlights the growing convergence of diagnostics and therapeutics, where biomarker testing serves as the foundation for personalized cancer care. Roche continues to invest heavily in developing integrated diagnostic solutions that support targeted therapies across a broad range of diseases, particularly in oncology.
By enabling clinicians to identify patients eligible for some of the most advanced immunotherapies and targeted treatments available today, the expanded approval has the potential to improve treatment outcomes, increase access to precision medicine, and support more effective management of complex cancers. The milestone also demonstrates the critical role that companion diagnostics play in advancing the next generation of cancer care and ensuring that innovative therapies reach the patients most likely to benefit from them.
Source: Roche press release
